KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

  • Products Id :- GDHC013SP
  • |
  • Pages: 24
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis


This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.

The briefing includes analysis of KOL opinion on the following topic areas-

- Efficacy & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients)

- Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients)

- Views on dose response for upadacitinib

Key Highlights

- Majority of KOLs had a positive opinion of upadacitinib's efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial

- Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial

- KOLs appeared unsure of upadacitinib's comparative efficacy vs. other JAK inhibitors, with many citing the need for head-to-head studies.


- The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

- Interviews performed in Q2 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Executive Summary


Research Panel Composition

Results & Implications


Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com






Upadacitinib, rheumatoid arthritis, adalimumab, baricitinib, JAK inhibitors, SELECT-COMPARE, tofacitinib

select a license
Single User License
USD 2500 INR 171550
Site License
USD 5000 INR 343100
Corporate User License
USD 7500 INR 514650



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com